An example is GSK2857916, an afucosylated IgG1 antibody as a non-cleavable MMAF conjugate targeting B-cell maturation antigen (BCMA), in the clinic for multiple myeloma and demonstrated potent anti-tumor activity while it harnessed multiple cytotoxic mechanisms [36,37]. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.